Prostatype Genomics

Prostatype Genomics is a Swedish medical technology company focused on molecular diagnostics for prostate cancer. Its core product is the Prostatype® Test System, a gene-expression test used to support treatment decisions after a prostate cancer diagnosis, with commercial activity in selected European markets and the United States.

— Prostatype Genomics
%
Prostatype® diagnostic test85% Molecular gene test used to assess prostate cancer risk and guide treatment decisions.
Testing services15% Commercial testing and related service revenue from running the Prostatype® workflow.

The company sells into healthcare settings that diagnose and treat prostate cancer, where clinicians need additional...

  • Hospitals and specialist clinicsprimary

    Buy the test to support prostate cancer treatment decisions for diagnosed patients

  • Clinical laboratoriessecondary

    Use or distribute the test workflow and related sample analysis services

  • Payers and reimbursement systemsprimary

    Not direct buyers in all cases, but reimbursement determines uptake and volume

  • Physicians and care teamsprimary

    Use the result as decision support when selecting treatment intensity

Prostatype Genomics is headquartered in Stockholm, Sweden, and operates from the Swedish market while commercializing...

  • •Headquartered in Stockholm, Sweden
  • •Commercial activity in selected European markets
  • •U.S. market is a key commercialization focus
  • •Local reimbursement and regulatory approval shape adoption
  • •Cross-border clinical evidence supports market expansion

The company’s strategy centers on commercializing Prostatype® in priority markets and building clinical evidence to...

01
U.S. commercializationshort-term

The U.S. is a large prostate cancer market and a major source of future adoption

02
Medicare reimbursementshort-term

Reimbursement is central to scaling test volume in the U.S. healthcare system

03
Clinical evidence generationmedium-term

Published data supports physician confidence, payer coverage, and partner interest

04
Strategic partnershipsmedium-term

Commercial partners can accelerate distribution and market access

The business depends on successful commercialization of a single core product, so adoption, reimbursement, and...

high

Commercialization and adoption risk

Revenue depends on physicians, labs, and payers adopting Prostatype® at scale

Scope
Single core product
Materiality
high
high

Reimbursement risk

Coverage decisions, especially Medicare, affect U.S. test utilization

Scope
U.S. market
Materiality
high
high

Competition and patent challenge risk

Other medtech companies may launch equivalent tests or challenge IP

Scope
Europe and U.S.
Materiality
high
high

Regulatory and study risk

Clinical evidence and approvals can be delayed or fail to meet expectations

Scope
Product launch and market access
Materiality
high
high

Impairment risk on intangible assets

Capitalized development costs depend on future commercialization cash flows

Scope
Balance sheet intangibles
Materiality
high
Capitalized development costs and impairment
If sales or cash flows disappoint, write-downs may accelerate
Going-concern and financing assumptions
Affects liquidity disclosures and continuity assumptions
K3 accounting framework
Shapes treatment of development costs, liabilities, and equity

ProPhase Labs, Inc.

PRPH · Pharmaceutical Preparations

VOLITIONRX LTD

VNRX · In Vitro & In Vivo Diagnostic Substances

Onconetix, Inc.

ONCO · Pharmaceutical Preparations

Protagenic Therapeutics, Inc.\new

PTIX · Pharmaceutical Preparations

NEOGENOMICS INC

NEO · Services-Testing Laboratories

PROTHENA CORP PUBLIC LTD CO

PRTA · Pharmaceutical Preparations

: 11/08/2026